Mid Penn Bancorp, Inc. Reports Record Second Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Mid Penn Bancorp, Inc. Reports Record Second Quarter Earnings and Declares Dividend

MILLERSBURG, Pa., July 23, 2014 (GLOBE NEWSWIRE) -- Mid Penn Bancorp, Inc. ("Mid Penn") (Nasdaq: MPB ), the parent company of Mid Penn Bank, today reported net income available to common shareholders for the quarter ended June 30, 2014 of $1,619,000, or $0.46 per common share, an increase of 26.6% over net income available to common shareholders of $1,279,000, or $0.37 per common share, reported during the same period in 2013. Through the first six months of 2014, Mid Penn's net income available to common shareholders was $3,043,000, or $0.87 per common share, an increase of 59.9% over net income available to common shareholders of $1,903,000, or $0.55 per common share reported during the same period in 2013. Mid Penn also reported increases of $30,831,000 in total assets, $30,094,000 in total net loans, and $44,938,000 in total non-time deposits over June 30, 2013.

                 
2014 Financial Highlights
(dollars in thousands, except per share data)
                 
      Change        
  06/30/14 06/30/13 $ %        
                 
Total Assets  $ 736,480  $ 705,649  $ 30,831 4.4%        
                 
Total Loans (net) 542,485 512,391 30,094 5.9%        
                 
Total Non-Time Deposits 504,070 459,132 44,938 9.8%        
                 
                 
  Quarter Ended Year-to-Date Ended
                 
      Change     Change
  06/30/14 06/30/13 $ % 06/30/14 06/30/13 $ %
                 
Net Interest Income  $ 6,751  $ 5,847  $ 904 15.5%  $ 13,023  $ 11,306  $ 1,717 15.2%
                 
Provision for Loan and Lease Losses 275 415 (140) -33.7% 822 910 (88) -9.7%
                 
Total Noninterest Income 774 838 (64) -7.6% 1,668 1,688 (20) -1.2%
                 
Total Noninterest Expense 5,068 4,612 456 9.9% 9,806 9,649 157 1.6%
                 
Net Income Available to Common Shareholders 1,619 1,279 340 26.6% 3,043 1,903 1,140 59.9%
                 
Diluted Earnings per Common Share 0.46 0.37 0.09 24.3% 0.87 0.55 0.32 58.2%
                 
Return on Average Equity 12.11% 10.33% N/A 17.2% 11.67% 7.81% N/A 49.5%

President's Statement

I am pleased to announce Mid Penn's financial results for the three and six months ended June 30, 2014.  The second quarter net income available to common shareholders of $1,619,000 was Mid Penn's highest quarterly earnings in our 146-year history, and helped propel Mid Penn to its highest six month earnings total ever. This represents a significant achievement in Mid Penn's progress. As can be seen above, year-to-date net income available to common shareholders improved 60% versus the comparable period last year. Net income available to common shareholders for the second quarter of 2014 increased 27% over the comparable period in 2013. Strong loan and deposit growth, an improved net interest margin, and control of expenses were the driving factors of success. We are encouraged by the financial results for the first half of 2014 and remain focused on quality asset growth, expanding low cost sources of funds, control of operating expenses, and increased noninterest income.

On behalf of the Board of Directors, I announce today that Mid Penn Bancorp, Inc. is declaring a cash dividend of $0.10 per common share based on second quarter earnings. This is an increase from the $0.05 per common share dividend declared for the second quarter of 2013 and our fifteenth consecutive quarter of paying a cash dividend. The dividend is payable August 25, 2014 to shareholders of record August 6, 2014.

Management considers subsequent events occurring after the balance sheet date for matters which may require adjustment to, or disclosure in, the consolidated financial statements.  The review period for subsequent events extends up to and including the filing date of a public company's consolidated financial statements when filed with the Securities and Exchange Commission ("SEC").  Accordingly, the financial information in this announcement is subject to change.

SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

Certain of the matters discussed in this press release may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and as such may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Mid Penn to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The words "expect", "anticipate", "intend", "plan", "believe", "estimate", and similar expressions are intended to identify such forward-looking statements.

Mid Penn's actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation:

  • The effects of future economic conditions on Mid Penn and its customers;
  • Governmental monetary and fiscal policies, as well as legislative and regulatory changes;
  • Future actions or inactions of the United States government, including a failure to increase the government debt limit or a prolonged shutdown of the federal government;
  • Possible impacts of the capital and liquidity requirements proposed by the Basel III standards and other regulatory pronouncements, regulations and rules;
  • The effect of changes in accounting policies and practices, as may be adopted by the regulatory agencies, as well as the Financial Accounting Standards Board and other accounting standard setters;
  • The risks of changes in interest rates on the level and composition of deposits, loan demand, and the values of loan collateral, securities and interest rate protection agreements, as well as interest rate risks;
  • The effects of economic deterioration and the prolonged economic recovery on current customers, specifically the effect of the economy on loan customers' ability to repay loans;
  • The effects of competition from other commercial banks, thrifts, mortgage banking firms, consumer finance companies, credit unions, securities brokerage firms, insurance companies, money market and other mutual funds and other financial institutions operating in Mid Penn's market area and elsewhere, including institutions operating locally, regionally, nationally and internationally, together with such competitors offering banking products and services by mail, telephone, computer and the internet;
  • The costs and effects of litigation and of unexpected or adverse outcomes in such litigation;
  • Technological changes;
  • Acquisitions and integration of acquired businesses;
  • The failure of assumptions underlying the establishment of reserves for loan and lease losses and estimations of values of collateral and various financial assets and liabilities;
  • Acts of war or terrorism;
  • Our ability to maintain compliance with the exchange rules of the NASDAQ Stock Market, Inc.;
  • Our ability to maintain the value and image of our brand and protect our intellectual property rights;
  • Disruptions due to flooding, severe weather, or other natural disasters or Acts of God;
  • Volatilities in the securities markets; and
  • Slow economic conditions.

All written or oral forward-looking statements attributable to Mid Penn are expressly qualified in their entirety by these cautionary statements.

Rory G. Ritrievi President Chief Executive Officer Kevin W. Laudenslager Vice President Treasurer Mid Penn Bancorp, Inc. 349 Union Street Millersburg, PA 17061 1-866-642-7736

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 431

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Brixton Metals Delivers Promising Drill Results in Thorn Project

Updated Category News Views 167

Brixton Metals' Latest Drill Results Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) recently unveiled its second batch of drill results from the 2025 exploration season. The company operates the Thorn Project, an underexplored district known for its potential in copper-gold porphyry deposits. Highlighting Impressive Assay Results The recent drilling at the...

Continue Reading
US Labor Market Stagnation: A Closer Look at 2025 Trends

Updated Category News Views 275

November Layoffs and Hiring Trends In November, layoffs by U.S. employers reduced significantly, signaling a shift in the job market dynamics. Yet, companies are still hesitant to recruit new employees, indicating a labor market that remains restrained due to various pressures. Businesses are facing challenges such as soft demand, tariff implications, and soaring...

Continue Reading
Dollar Steady Amid Global Market Uncertainty and Yuan Weakness

Updated Category News Views 127

Asian Currency Markets React to U.S. Dollar Strength In the bustling arena of Asian currencies, the atmosphere is charged with anticipation as investors monitor the situation in China regarding potential economic stimulus measures. Meanwhile, the U.S. dollar is exhibiting remarkable strength, currently hovering near a two-and-a-half month high. This rise comes in light of...

Continue Reading
Understanding Recent Insider Trades at Omega Healthcare Invts

Updated Category News Views 75

Examining Insider Trades at Omega Healthcare Invts Recently, a notable insider trade involving Omega Healthcare Invts has drawn attention. Chief Operating Officer Daniel Booth executed a significant transaction, selling 56,725 shares as disclosed through an SEC filing. This particular sale took place on a recent date and revealed a total transaction value of $2,283,181....

Continue Reading
Exploring Future Growth in Healthcare Digital Payments Market

Updated Category News Views 150

Introduction to Digital Payments in Healthcare The transformation in the realm of healthcare is not just about treatments and services; it extends deeply into how payments are managed. The Digital Payment in Healthcare Market is evolving, with an anticipated growth in value reaching USD 61,521.8 Million by the year 2033. This incredible increase is projected to occur at a...

Continue Reading